TSX VENTURE: SSS has undertaken an offering of units, each unit being comprised of one common share and a portion of a common share purchase warrant.
- The offering to be effected in each of the Canadian provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia by way of a prospectus supplement to SCT’s base shelf prospectus of 3/1/11;
- These securities have not been registered under the United States Securities Act of 1933;
- Bloom Burton & Co. and Euro Pacific Canada are acting as agents for the offering.
The Bottom Line: VENTURE: SSS develops therapies that utilize drugs to stimulate a patient’s own stem cells to repair brain and nerve function lost due to disease or injury. Their future clinical programs are in numerous neurological diseases such as stroke, traumatic brain injury, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and ALS. Yet another unit financing, playing the hold of the warrant option or the stock?